Yu, Anthony
Birkemeier, Krista L.
Mills, J. Rebecca
Kuo, Tiffany
Tachikawa, Nina
Dai, Feng
Thakkar, Karishma
Cable, Christian
Brenner, Allison
Godley, Paul J. http://orcid.org/0000-0003-2113-1934
Funding for this research was provided by:
Pfizer
Article History
Received: 16 February 2024
Accepted: 24 April 2024
First Online: 21 May 2024
Declarations
:
: J. Rebecca Mills, Nina Tachikawa, Feng Dai, and Allison Brenner are employees of and shareholders in Pfizer, Inc. Anthony Yu, Krista L. Birkemeier, Tiffany Kuo, Karishma Thakkar, Christian Cable, and Paul J. Godley declare that they have no competing interests.
: The Baylor Scott & White institutional review board assessed the protocol (023-032) to qualify for expedited review as it posed minimal risk to study participants. All participants provided informed consent to participate in the study. The informed consent documents used during the informed consent process and any participant recruitment materials were reviewed and approved by Pfizer and by the institutional review board/independent ethics committee before use. The Baylor Scott & White institutional review board approved this study (IRB ID: 023-032). This study was conducted at the Baylor Scott & White Temple hospital. This evaluation was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor and follow generally accepted research practices described in Good Practices for Outcomes Research issued by the International Society for Pharmacoeconomics and Outcomes Research and in accordance with the Helsinki Declaration of 1964 and its later amendments.